Servier’s muscular dystrophy bet failed as its experimental drug sevasemten did not slow a rare form of muscular dystrophy in a pivotal Phase 3 trial. The company bought the program from Edgewise Therapeutics for $1.55 billion upfront plus up to about $1 billion in potential milestones, making the setback a major inflection point for Servier’s late-stage strategy. In the GRAND CANYON trial, Servier said results were not aligned with findings from earlier studies and is conducting a comprehensive analysis of the dataset together with relevant prior clinical information. Becker muscular dystrophy still lacks approved disease-modifying treatments, leaving patients reliant on ongoing research. The outcome also underscores the gap between earlier randomized signals and later pivotal endpoints in ultra-rare neuromuscular indications.